The Board of Directors of Alcoa (NYSE:AA) declared a quarterly common stock dividend of 3 cents per share payable February 25, 2016 to holders of record of the common stock at the close of business on February 5, 2016; dividend of 93.75 cents per share on Alcoa’s $3.75 cumulative preferred stock (“Class A Stock”) payable April 1, 2016 to holders of record of the Class A Stock at the close of business on March 11, 2016; and a dividend of $6.71875 per share on Alcoa’s 5.375% Class B Mandatory Convertible Preferred Stock (“Class B Stock”) payable April 1, 2016 to holders of record of the Class B Stock at the close of business on March 15, 2016
Alcoa Inc. (NYSE:AA) belongs to Basic Materials sector. Its net profit margin is -0.80% and weekly performance is 2.82%. On last trading day company shares ended up at $8.76. Alcoa Inc. (NYSE:AA) distance from 50-day simple moving average (SMA50) is 6.51%.
Neothetics, Inc. (NASDAQ:NEOT), announced that George Mahaffey offered his resignation as Chief Executive Officer and Chairman of the Board, effective immediately. The board has formed a committee to oversee day to day operations until a replacement is found. The Company also announced it is evaluating a path forward with a modified formulation of its lead asset LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat. Neothetics will provide a more detailed update in its 10-K and 4Q2015 release.
Neothetics, Inc. (NASDAQ:NEOT) shares decreased -7.15% in last trading session and ended the day at $0.61. NEOT return on assets is -55.10%. Neothetics, Inc. (NASDAQ:NEOT) quarterly performance is -93.03%.
TEGNA Inc.’s (NYSE: TGNA) Board of Directors declared a dividend of $0.14 per share, payable on April 1, 2016 to stockholders of record as of the close of business on March 4, 2016.
On 24 February, TEGNA Inc. (NYSE:TGNA) shares decreased -0.90% and was closed at $24.15. TGNA EPS growth in last 5 year was -7.90%. TEGNA Inc. (NYSE:TGNA) year to date (YTD) performance is -5.37%.
On 17 February, Enzymotec Ltd. (NASDAQ:ENZY) reported Gross margin (equity method) for the fourth quarter of 2015 increased 299 basis points to 61.4%, from 58.5% for the fourth quarter of 2014 primarily due to a change in product mix. Research and development expenses for the fourth quarter of 2015 increased 21.3% to $1.8 million, from $1.5 million for the fourth quarter of 2014, primarily as a result of an increase of $0.2 million related to expenses in respect of VAYA Pharma clinical trials.
Enzymotec Ltd. (NASDAQ:ENZY) ended the last trading day at $8.01. Company weekly volatility is calculated as 8.41% and price to cash ratio as 6.89. Enzymotec Ltd. (NASDAQ:ENZY) showed a weekly performance of -0.12%.
Accuray Incorporated (NASDAQ:ARAY), announced that Joshua H. Levine, President and Chief Executive Officer, is scheduled to present at the 36th Annual Cowen and Company Health Care Conference in Boston, MA on Monday, March 7, 2016 at 3:20pm ET.
Accuray Incorporated (NASDAQ:ARAY) shares advanced 2.96% in last trading session and ended the day at $5.21. ARAY Gross Margin is 39.10% and its return on assets is -5.90%. Accuray Incorporated (NASDAQ:ARAY) quarterly performance is -23.38%.